A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus

Venkatesulu, Bhanu Prasad; Chandrasekar, Viveksandeep Thoguluva; Girdhar, Prashanth; Advani, Pragati G.; Sharma, Amrish; Elumalai, Thiraviyam; Hsieh, Cheng‐En; Elghazawy, Hagar; Verma, Vivek; Krishnan, Sunil

doi:10.1093/jncics/pkaa102

Cited by 91 publications

(87 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data from the systematic review of 31 studies show 181,323 patients with COVID-19, of whom 23,736 patients with cancer confirmed that they are at increased risk of mortality and morbidity. The mortality was highest in hematological malignancies (OR 2.43) followed by lung cancer (OR 1.8) with no association between a particular type of oncologic therapy ( 28 ).…”

Section: Sars-cov-2 Virusmentioning

confidence: 97%

Viral Infection and Lung Cancer Immunotherapy

2021

View full text Add to dashboard Cite

Immunotherapy with immune checkpoint inhibitors (mainly anti-PD1 and anti-PDL1 monoclonal antibodies) became a standard of care in non-small cell lung cancer (NSCLC) patients. Most of the clinical trials excluded patients with hepatitis B (HBV), hepatis C (HCV), and human immunodeficiency virus (HIV) active infection (1–10). Despite the progress in treatment of these infections, they remain an unresolved clinical problem when lung cancer immunotherapy should be initiated in an NSCLC patient. This manuscript summarizes the data from the literature concerning this subgroup of patients including the rationale for immunotherapy initiation depending on the HBV, HCV, or HIV infection status; the risk of adverse events; and the efficacy compared to non-infected patients. One of the crucial questions is how the candidates to immunotherapy should be screened for HBV, HCV, and HIV infections. The year 2020 brought the world a new but dynamic viral problem—severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). The incorporation of known data in oncology guidelines became a burning need, and then, which group of the infected patients can be treated with immunotherapy despite the infection. Oncologists should also know if these patients should receive antiviral therapy and what are the safe combinations in these settings. We also indicate which of the adverse events should be monitored carefully during checkpoint inhibitor treatment.

show abstract

Section: Sars-cov-2 Virusmentioning

confidence: 97%

Viral Infection and Lung Cancer Immunotherapy

2021

View full text Add to dashboard Cite

show abstract

“…Patients with cancer have a worse prognosis and mortality when infected with SARS-CoV-2 compared to otherwise healthy people, and thus belong to the high-risk populations that need to be protected from infection 8 . This has created a dilemma when it comes to the continuation of cancer treatment in patients infected with SARS-CoV-2, as oncologists have to balance the risk of cancer progression with that of poorer post-COVID-19 outcomes.…”

Section: Covid-19 and Cancer Care In Indiamentioning

confidence: 99%

COVID-19 and cancer care in India

et al. 2021

View full text Add to dashboard Cite

“…A systematic review of 31 studies and meta-analysis of 181,323 patients from 26 studies involving 23,736 cancer patients showed that cancer patients with COVID-19 have a higher likelihood of death. The mortality was highest in hematological malignancies followed by lung cancer [6]. However, the authors did not compare the mortality rate between cancer and individuals without cancer.…”

Section: Introductionmentioning

confidence: 98%

Hematologic Neoplasms As Risk Factor For Severe COVID-19: A Systematic Review Protocol

Hokama

Mendes

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Patients with hematologic neoplasm may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. However, the studies bring together patients with hematologic neoplasms and solid tumors into a single group, making no distinction about the types of hematological tumors and their treatments. This systematic review is designed to explore the risk of severe COVID-19 in patients with hematologic neoplasm. Studies about patients, adult or children, with hematologic neoplasm and COVID-19 will be included. Methods: A systematic review according to Joanna Briggs Institute methodology for systematic reviews of etiology and risk will be performed. The review will consider as participants adults or children with COVID-19 infection detected by RT-PCR or serology (SARS-CoV-2 antibody). We will be included studies without routine labs confirmation of COVID-19 if the patients presented clinical/physical exam and computed tomography suggesting COVID-19. The exposure of interest will be hematologic neoplasm, which include lymphomas, acute and chronic leukemias, myeloma, myelodysplastic syndrome, and myeloproliferative diseases. We will consider cohort, case-control, analytical cross-sectional studies. Outcomes among patients with COVID-19 are critical symptoms, hospitalizations, intensive care unit admissions, mechanical ventilation and deaths. We will exclude studies with other neoplasms than hematologic neoplasms. Search strategies have been created for the Embase, Medline and LILACS. Two reviewers independently will assess the studies for their eligibility, will extract data and will evaluate their risk of bias. Similar outcomes measured in at least two studies will be plotted in the meta-analysis using the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information. Discussion: This systematic review aims to evaluate if patients with hematologic neoplasm may be at elevated risk of severe COVID-19. This review will differ from the previous ones because we will include controlled studies and groups with only hematologic neoplasm, excluding other cancers. The main hypothesis of our research is that not all hematological cancer patients have high risk of severe COVID-19. Trial registration number: PROSPERO CRD42020199318.

show abstract

A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus

Cited by 91 publications

References 31 publications

Viral Infection and Lung Cancer Immunotherapy

Viral Infection and Lung Cancer Immunotherapy

COVID-19 and cancer care in India

Hematologic Neoplasms As Risk Factor For Severe COVID-19: A Systematic Review Protocol

Contact Info

Product

Resources

About